Citation: | Hana Chmelařová, Maria Carmen Catapano, Jean-Christophe Garrigues, František Švec, Lucie Nováková. Advancing drug safety and mitigating health concerns: High-resolution mass spectrometry in the levothyroxine case study[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.100970 |
[1] |
M. Khalikova, J. Jires, O. Horacek, et al., What is the role of current mass spectrometry in pharmaceutical analysis? Mass Spectrom. Rev. (2023).
|
[2] |
N. Kaur and R. Suryanarayanan, Levothyroxine Sodium Pentahydrate Tablets-Formulation Considerations, J. Pharm. Sci. 110 (2021): p. 3743-3756.
|
[3] |
I. Ledeți, M. Romanescu, D. Circioban, et al., Stability and compatibility studies of levothyroxine sodium in solid binary systems-instrumental screening, Pharmaceutics 12 (2020), 58.
|
[4] |
H. Patel, A. Stalcup, R. Dansereau, et al., The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets, Int. J. Pharm. 264 (2003) 35-43.
|
[5] |
J.W. Collier, R.B. Shah, A. Gupta, et al., Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate, AAPS PharmSciTech 11 (2010) 818-825.
|
[6] |
V. Neu, C. Bielow, I. Gostomski, et al., Rapid and comprehensive impurity profiling of synthetic thyroxine by ultrahigh-performance liquid chromatography-high-resolution mass spectrometry, Anal. Chem. 85 (2013) 3309-3317.
|
[7] |
V. Neu, C. Bielow, K. Reinert, et al., Ultrahigh-performance liquid chromatography-ultraviolet absorbance detection-high-resolution-mass spectrometry combined with automated data processing for studying the kinetics of oxidative thermal degradation of thyroxine in the solid state, J. Chromatogr. A 1371 (2014) 196-203.
|
[8] |
M. Ruggenthaler, J. Grass, W. Schuh, et al., Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis, J. Pharm. Biomed. Anal. 135 (2017) 140-152.
|
[9] |
V. Neu, C. Bielow, P. Schneider, et al., Investigation of reaction mechanisms of drug degradation in the solid state: A kinetic study implementing ultrahigh-performance liquid chromatography and high-resolution mass spectrometry for thermally stressed thyroxine, Anal. Chem. 85 (2013) 2385-2390.
|
[10] |
S. Benvenga, A. Carle, Levothyroxine formulations: Pharmacological and clinical implications of generic substitution, Adv. Ther. 36 (2019) 59-71.
|
[11] |
N. Kaur, R. Suryanarayanan, Investigating the influence of excipients on the stability of levothyroxine sodium pentahydrate, Mol. Pharm. 18 (2021) 2683-2693.
|
[12] |
E. Fliers, B. Demeneix, A. Bhaseen, et al., European thyroid association (ETA) and thyroid federation international (TFI) joint position statement on the interchangeability of levothyroxine products in EU countries, Eur. Thyroid J. 7 (2018) 238-242.
|
[13] |
H.S. Shah, K. Chaturvedi, M. Hamad, et al., New insights on solid-state changes in the levothyroxine sodium pentahydrate during dehydration and its relationship to chemical instability, AAPS PharmSciTech 20 (2019), 39.
|
[14] |
M.L. Hamad, W. Engen, K.R. Morris, Impact of hydration state and molecular oxygen on the chemical stability of levothyroxine sodium, Pharm. Dev. Technol. 20 (2015) 314-319.
|
[15] |
N. Kaur, V.G. Young Jr, Y. Su, et al., Partial dehydration of levothyroxine sodium pentahydrate in a drug product environment: Structural insights into stability, Mol. Pharm. 17 (2020) 3915-3929.
|
[16] |
S.S. Bharate, S.B. Bharate, A.N. Bajaj, Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: A comprehensive review, J. Excip. Food Chem. 1 (2010) 3-26.
|
[17] |
K. Burman, J. Hennessey, M. McDermott, et al., The FDA revises requirements for levothyroxine products, Thyroid 18 (2008) 487-490.
|
[18] |
P. Colucci, C.S. Yue, M. Ducharme, et al., A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism, Eur. Endocrinol. 9 (2013) 40-47.
|
[19] |
H.-P. Lipp, U. Hostalek, A new formulation of levothyroxine engineered to meet new specification standards, Curr. Med. Res. Opin. 35 (2019) 147-150.
|
[20] |
B. Casassus, Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ-Brit. Med. J. 360 (2018).
|
[21] |
D. Concordet, P. Gandia, J.L. Montastruc, et al., Levothyrox® new and old formulations: Are they switchable for millions of patients? Clin. Pharmacokinet. 58 (2019) 827-833.
|
[22] |
U. Gottwald-Hostalek, W. Uhl, P. Wolna, et al., New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials, Curr. Med. Res. Opin. 33 (2017) 169-174.
|
[23] |
Safety Information. Eltroxin Formulation Change. Eltroxin Formulation Change (medsafe.govt.nz) (Accessed 23 January 2024).
|
[24] |
U. Gottwald-Hostalek, Y. Tayrouz, Real world clinical experience with a new formulation of levothyroxine engineered to meet new and stricter regulatory requirements, Curr. Med. Res. Opin. 37 (2021) 2093-2098.
|
[25] |
European Pharmacopoeia 11.0, in Levothyroxine sodium, Ph. Eur. 11.0. 2023, European Directorate for the Quality of Medicines Council of Europe: Strasbourg, France, (2023), 3236-3238.
|
[26] |
A.G. Kazemifard, D.E. Moore, A. Aghazadeh, Identification and quantitation of sodium-thyroxine and its degradation products by LC using electrochemical and MS detection, J. Pharm. Biomed. Anal. 25 (2001) 697-711.
|
[27] |
M.K. Sreeramoju, G.A. Digenis, J. May, Detection and characterization of an unknown impurity in levothyroxine oral solution product: Implications for formulation development and storage, J. Pharm. Sci. 110 (2021) 682-686.
|
[28] |
J. Guo, T. Huan, Comparison of full-scan, data-dependent, and data-independent acquisition modes in liquid chromatography-mass spectrometry based untargeted metabolomics, Anal. Chem. 92 (2020) 8072-8080.
|
[29] |
F. Fenaille, P. Barbier Saint-Hilaire, K. Rousseau, et al., Data acquisition workflows in liquid chromatography coupled to high resolution mass spectrometry-based metabolomics: Where do we stand? J. Chromatogr. A 1526 (2017) 1-12.
|
[30] |
C. Fernandez-Costa, S. Martinez-Bartolome, D.B. McClatchy, et al., Impact of the identification strategy on the reproducibility of the DDA and DIA results, J. Proteome Res. 19 (2020) 3153-3161.
|
[31] |
B. Worley, R. Powers, Multivariate analysis in metabolomics, Curr. Metabolomics 1 (2013) 92-107.
|
[32] |
European Pharmacopoeia 11.0, in Magnesium stearate, Ph. Eur. 11.0. 2023, European Directorate for the Quality of Medicines Council of Europe: Strasbourg, France, (2023), 3307–3309.
|
[33] |
C.D. Calvano, M. Bianco, G. Ventura, et al., Analysis of phospholipids, lysophospholipids, and their linked fatty acyl chains in yellow lupin seeds (Lupinus luteus L.) by liquid chromatography and tandem mass spectrometry, Molecules 25 (2020), 805.
|
[34] |
M. Gayral, M. Fanuel, H. Rogniaux, et al., The spatiotemporal deposition of lysophosphatidylcholine within starch granules of maize endosperm and its relationships to the expression of genes involved in endoplasmic reticulum-amyloplast lipid trafficking and galactolipid synthesis, Plant Cell Physiol. 60 (2019) 139-151.
|
[35] |
S.H. Lee, J.N. BeMiller, Lysophosphatidylcholine identified as channel-associated phospholipid of maize starch granules, Cereal Chem. 85 (2008) 776-779.
|
[36] |
S. Wang, C. Chao, J. Cai, et al., S. Wang, C. Chao, J. Cai, et al., Starch-lipid and starch-lipid-protein complexes: A comprehensive review, Compr. Rev. Food Sci. Food Saf. 19 (2020) 1056-1079.
|
[37] |
P. van Hoogevest, Review - An update on the use of oral phospholipid excipients, Eur. J. Pharm. Sci. 108 (2017) 1-12.
|
[38] |
J. Li, X. Wang, T. Zhang, et al., A review on phospholipids and their main applications in drug delivery systems, Asian J. Pharm. Sci. 10 (2015) 81-98.
|
[39] |
K. Kuche, N. Bhargavi, C.P. Dora, et al., Drug-phospholipid complex-a go through strategy for enhanced oral bioavailability, AAPS PharmSciTech 20 (2019), 43.
|
[40] |
A. Aleskndrany, I. Sahin, The effects of Levothyroxine on the structure and dynamics of DPPC liposome: FTIR and DSC studies, Biochim. Biophys. Acta BBA Biomembr. 1862 (2020), 183245.
|
[41] |
European Pharmacopoeia 11.0, in Maize starch, Ph. Eur. 11.0. 2023, European Directorate for the Quality of Medicines Council of Europe: Strasbourg, France, (2023), 3311-3312.
|
[42] |
M. Gayral, B. Bakan, M. Dalgalarrondo, et al., Lipid partitioning in maize (Zea mays L.) endosperm highlights relationships among starch lipids, amylose, and vitreousness. , J. Agric. Food Chem. 63 (2015) 3551-3558.
|
[43] |
anonymous. Rapport d’analyse de conformité de la nouvelle formulation du Levothyrox effectué par les laboratoires de l’ANSM Actualité - L’ANSM a réalisé dans ses laboratoires plusieurs contrôles sur la composition de Levothyrox nouvelle formule qui ont confirmé sa bonne qualité - Communiqué - ANSM (sante.fr) (Accessed 23 January 2024).
|
[44] |
E.I. Yousif, M.G.E. Gadallah, A.M. Sorour, Physico-chemical and rheological properties of modified corn starches and its effect on noodle quality, Ann. Agric. Sci. 57 (2012) 19-27.
|
[45] |
Y. Yang, Y. Peng, Q. Chang, et al., Selective identification of organic iodine compounds using liquid chromatography-high resolution mass spectrometry, Anal. Chem. 88 (2016) 1275-1280.
|
[46] |
L. Sleno, The use of mass defect in modern mass spectrometry, J. Mass Spectrom. 47 (2012) 226-236.
|
[47] |
V. Das Gupta, C. Odom, C. Bethea, et al., Effect of excipients on the stability of levothyroxine sodium tablets, J. Clin. Pharm. Ther. 15 (1990) 331-336.
|
[48] |
I. Gostomski, R. Braun, C.G. Huber, Detection of low-abundance impurities in synthetic thyroid hormones by stationary phase optimized liquid chromatography-mass spectrometry, Anal. Bioanal. Chem. 391 (2008) 279-288.
|